Curetis Reports Financial Results for the First Six Months of 2019

    NEXT STORY
    Summit Announces Publication of Editorial in Future Microbiology Advocating for Innovation in Antibiotic Development to Drive Stewardship Focus on Improving Patient Outcomes
    PREV STORY
    FDA grants Breakthrough Therapy Designation for Roche’s Gazyva (obinutuzumab) in Lupus Nephritis
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Aduro Biotech Appoints Oncology Expert and Industry Veteran Natalie Sacks, M.D. as Chief Medical Officer

    BERKELEY, Calif., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today announced ...

    author_avatar
    NASDAQ Market News

    Third Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer

    Kisqali plus fulvestrant demonstrated superior efficacy, with a median PFS of 20.5 months vs. ...

    author_avatar
    NASDAQ Market News

    Immunomedics Provides Corporate Update

    author_avatar
    NASDAQ Market News